Equities Analysts Issue Forecasts for ALLO Q1 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – William Blair issued their Q1 2026 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Friday, March 14th. William Blair analyst S. Corwin expects that the company will post earnings of ($0.29) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06.

ALLO has been the topic of several other research reports. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research note on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.40.

Allogene Therapeutics Stock Performance

ALLO opened at $1.85 on Monday. The stock has a market capitalization of $387.89 million, a P/E ratio of -1.19 and a beta of 1.02. The company’s 50-day simple moving average is $1.93 and its two-hundred day simple moving average is $2.31. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.74.

Insider Buying and Selling

In related news, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is owned by corporate insiders.

Institutional Trading of Allogene Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Allogene Therapeutics by 18.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company’s stock worth $576,000 after buying an additional 41,753 shares during the last quarter. Two Sigma Advisers LP increased its stake in Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after purchasing an additional 291,800 shares during the period. Rafferty Asset Management LLC increased its stake in Allogene Therapeutics by 15.9% in the fourth quarter. Rafferty Asset Management LLC now owns 367,445 shares of the company’s stock worth $783,000 after purchasing an additional 50,499 shares during the period. Raiffeisen Bank International AG purchased a new stake in Allogene Therapeutics in the fourth quarter worth $903,000. Finally, ProShare Advisors LLC increased its stake in Allogene Therapeutics by 25.6% in the fourth quarter. ProShare Advisors LLC now owns 46,082 shares of the company’s stock worth $98,000 after purchasing an additional 9,388 shares during the period. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).